Obesity is a serious and growing health problem in the United States. Obesity is associated with health problems such as type-2 diabetes and cardiovascular disease, leading to decreased quality of life and increased mortality. Given the health and quality-of-life effects of obesity, developing effective treatments clearly is an important goal. This study plans to learn more about the effects of an investigational new drug (DMXB-A (3-(2,4-dimethoxybenzylidene anabaseine)) and its effects on obesity. The study drug has similar effects to nicotine. Since nicotine has been found to affect appetite, the investigators are interested in studying effects of the study drug, which has some similarities to nicotine, on how your brain responds to such things as pictures of food. The study drug has not been approved by the Food and Drug Administration (FDA), and is considered experimental.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
OTHER
Masking
DOUBLE
Enrollment
61
150 mg DMXB-A (3-(2,4-dimethoxybenzylidene anabaseine) b.i.d. for 12 weeks.
Placebo capsules b.i.d. for 12 weeks
University of Colorado
Denver, Colorado, United States
Neuronal Response to Visual Food Cues
Neuronal response (insula) while viewing visual food cues
Time frame: 14 weeks
Resting-state Neuronal Response
Neuronal response (default mode network) during rest
Time frame: 14 weeks
Body Weight
Body weight
Time frame: 14 weeks
Fat Mass
Fat mass
Time frame: 14 weeks
Appetite Rating
Hunger ratings via VAS scale (0-100)
Time frame: 14 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.